Progenics Pharmaceuticals, Inc.

Progenics Pharmaceuticals, Inc., an oncology company, engages in the development and commercialization of various targeted medicines and artificial intelligence to find, fight, and follow cancer. The company’s commercial products comprise AZEDRA for the treatment of patients with unresectable locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy; and oral and subcutaneous formulations of RELISTORfor the treatment of opioid-induced constipation. Its products also include AZEDRA, 1095, and PSMA TTC that are therapeutic agents to treat cancer; prostate-specific membrane antigen targeted imaging agents for prostate cancer; and imaging analysis technology. The company was founded in 1986 and is headquartered in New York, New York. Progenics Pharmaceuticals, Inc. is a subsidiary of Lantheus Holdings, Inc.